Value profile for respiratory syncytial virus vaccines and monoclonal antibodies
Jessica A Fleming,Ranju Baral,Deborah Higgins,Sadaf Khan,Sonali Kochar,You Li,Justin R Ortiz,Thomas Cherian,Daniel Feikin,Mark Jit,Ruth A Karron,Rupali J Limaye,Caroline Marshall,Patrick K Munywoki,Harish Nair,Lauren C Newhouse,Bryan O Nyawanda,Clint Pecenka,Katie Regan,Padmini Srikantiah,Rachel Wittenauer,Heather J Zar,Erin Sparrow
DOI: https://doi.org/10.1016/j.vaccine.2022.09.081
IF: 4.169
Vaccine
Abstract:Respiratory syncytial virus (RSV) is the predominant cause of acute lower respiratory infection (ALRI) in young children worldwide, yet no licensed RSV vaccine exists to help prevent the millions of illnesses and hospitalizations and tens of thousands of young lives taken each year. Monoclonal antibody (mAb) prophylaxis exists for prevention of RSV in a small subset of very high-risk infants and young children, but the only currently licensed product is impractical, requiring multiple doses and expensive for the low-income settings where the RSV disease burden is greatest. A robust candidate pipeline exists to one day prevent RSV disease in infant and pediatric populations, and it focuses on two promising passive immunization approaches appropriate for low-income contexts: maternal RSV vaccines and long-acting infant mAbs. Licensure of one or more candidates is feasible over the next one to three years and, depending on final product characteristics, current economic models suggest both approaches are likely to be cost-effective. Strong coordination between maternal and child health programs and the Expanded Program on Immunization will be needed for effective, efficient, and equitable delivery of either intervention. This 'Vaccine Value Profile' (VVP) for RSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships and multi-lateral organizations, and in collaboration with stakeholders from the WHO headquarters. All contributors have extensive expertise on various elements of the RSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.